Atrial fibrillation, atrial flutter. Atrial fibrillation and flutter
Conditions
Interventions
Intervention 1: Intervention group: Avecinna defibrillator. In both groups patients will be sedated. antiarhythmic drug use will be recorded in CRF forms. anti-arrhythmic drugs will not be used as pre
Sponsors
Avecinna co
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Age >18 years old Atrial fibrillation or flutter indication for cardioversion Atrial fibrillation or flutter will be confirmed by an electrophysiologist using 12 lead standard ECG. Cardioversion will be conducted at the discretion of the electrophysiologist. All patients are required to receive at least 4 weeks of antio coagulation or left atrial thrombus is ruled out by trans esophageal echocardiography
Exclusion criteria
Exclusion criteria: Requiring emergeny cardioversion Hemodynamic instability Chest pain or suspicion of acute coronary syndrome Hypokalemia Digoxin toxicity Pregnancy or breastfeeding No informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of sinus rhythm conversion. Timepoint: After cardioversion. Method of measurement: ECG. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of times shock is required in experimental and standard device. Timepoint: After start of the cardioversion process. Method of measurement: Number.;Safety: any inflammation, burn, pain, or electrocution in experimental device compared to standard device. comparison of ventricular arrhythmias, bradycardia, or asystole.comparison of any other adverse effects. Timepoint: Immeadiately after shock. Method of measurement: Observation by the cardiologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad Masoud Kabir
Tehran University of Medical Sciences
Outcome results
None listed